P650: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES. (23rd June 2022) - Linton, K.; Collins, G. P.; El-Sharkawi, D.; Mous, R.; Forconi, F.; Tan, M.; Nandakumar, S.; Meredith, E.; Jameson, K. L.; Injac, S. G.; Doorduijn, J.